Biocon Generics (BGI), a wholly owned subsidiary of Indian biopharmaceutical company Biocon Ltd, has unveiled its new manufacturing facility in Cranbury, New Jersey, US.
Biocon acquired the site from Eywa Pharma for $7.7m in September 2023. Since the purchase, it has invested over $30m to establish an advanced plant capable of producing up to two billion tablets annually. The company has already commercialised a few products from the facility, with additional launches planned for the future.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The new facility aims to diversify Biocon’s manufacturing capabilities, enhance its supply chain, and expand its global presence. The facility also advances the company’s US operations by providing quicker access to essential therapies. Additionally, it strengthens relationships with partners and healthcare providers, ultimately benefiting patients nationwide.
Kiran Mazumdar-Shaw, chairperson of Biocon, remarked that the new facility marked a new chapter in Biocon’s journey of global expansion.
Siddharth Mittal, CEO and managing director of Biocon, stated that the strategic investment brought them closer to patients, healthcare providers, and partners.
“The proximity allows us to deliver our vertically integrated medicines more efficiently to patients across the US and other markets. It also ensures supply chain resilience, enabling us to advance our mission of expanding access to affordable therapies worldwide,” he added.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataPhil Murphy, Governor of New Jersey, expressed his gratitude towards Biocon for its decision to open its first US manufacturing facility in New Jersey.
“For years, Biocon has provided high-quality medicines and treatments to millions of patients across the globe. This state-of-the-art facility marks a significant moment in Biocons’s global expansion and reinforces New Jersey’s reputation as the medicine chest to the world,” Murphy added.
The Cranbury facility adds to the company’s growing presence in the US. Last year, in September 2024, it opened its North American headquarters in Bridgewater, New Jersey.
